ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

NCT04326426 · tracked via the Priya Life Science USA tracker

Sponsor

Vanda Pharmaceuticals

Phase

Phase 3

Started

2020-04-13

Last updated

2020-04-20

Condition(s) studied

Coronavirus Infection

Investigational drug(s) / intervention(s)

TradipitantPlacebo

Tradipitant: Neurokinin-1 antagonist

Placebo: Matching placebo

Study summary

This is a randomized, double-blind placebo-controlled trial to investigate the efficacy and safety of tradipitant 85 mg orally given twice daily to treat inflammatory lung injury associated with severe or critical COVID-19 infection.

On evaluation for enrollment, participant will need to meet all inclusion and exclusion criteria. If participant consents, they will be randomized 1:1 to treatment with either tradipitant 85 mg PO BID or placebo in addition to standard of care for COVID-19 infection as per the protocol at the treating hospital. NEWS 2 will be assessed at screening and daily following randomization. Inflammatory lab markers as detailed should be collected once per day in the morning, preferably at the same time every morning. All enrolled participants will have whole blood collected for whole genome sequencing.

Eligibility

Sex

ALL

Min age

18 Years

Max age

90 Years

Healthy volunteers

Inclusion Criteria: * Adults aged 18-90 * Confirmed laboratory COVID-19 infection by RT-PCR * Meeting severe or critical criteria of COVID-19 infection as defined at treating hospital * Confirmed pneumonia by chest radiograph or computed tomography * Fever defined as temperature ≥ 36.6 °C armpit, ≥ 37.2 °C oral, or ≥ 37.8 °C rectal * Oxygen saturation less than 92% Exclusion Criteria: * Recent use of illicit drugs or alcohol abuse * Known allergy to tradipitant or other neurokinin-1 antagonists * Pregnancy * Known HIV, HBV, or HCV infection * Malignant tumor, other serious systemic diseases * Inability to provide informed consent or to have an authorized relative or designated person provide informed consent, or to comply with the protocol requirements

Primary outcome measure(s)

Time to improvement on a 7-point ordinal scale as compared to baseline — 14 days or discharge

Trial sites (1)

Facility	City	Region	Status
Lenox Hill Hospital Northwell Health	New York	New York

More Vanda Pharmaceuticals trials in the USA

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis Active, not recruiting

Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances Recruiting

Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder Active, not recruiting

Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient Active, not recruiting

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension Recruiting

Other trials for the same condition

SPI-1005 Treatment in Moderate COVID-19 Patients Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04326426 on ClinicalTrials.gov ↗ ← All trials in the USA